Role of quantitative, multiplexed, targeted proteomics in determining variant-specific SARS-CoV-2 antibody response

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the development and rollout of the world’s fastest and largest global vaccination programs. However, the waning of immunity over time, along with the emergence of several SARS-CoV-2 variants of concern (VOCs), highlights the requirement of better informative testing that will in turn help to determine the need and timing of a booster vaccination.

Study: Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response. Image Credit: Lightspring/ShutterstockStudy: Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response. Image Credit: Lightspring/Shutterstock

Although first-generation tests were rolled out, they were found to overestimate the actual protective immunity against the VOCs. Current technologies that measure neutralizing antibodies (NAbs) were found to have poor clinical utility while serological approaches (ELISA or ECLIA) were found to measure only a part of the antibody response.

A new study published in the pre-print server medRxiv* developed a ‘bait and capture’ system which was further followed by a multiplexed and targeted proteomic liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses for the comparison of immune correlates in response to vaccination, natural infection, as well as protection against the VOCs.

About the study

The current study was performed using serum samples from the COVIDsortium study where longitudinal immunological analysis had already been performed.  The study included 25 healthcare workers (HCWs) with previous laboratory evidence of wild-type SARS-CoV-2 infection and 26 HCWs with no evidence of SARS-CoV-2 infection.

Thereafter, SARS-CoV-2 immunocomplex assay was carried out followed by immunocomplex protein digestion. Targeted LC-MS/MS analysis was carried out using the digested samples. Finally, an authentic virus neutralization assay was carried out.

Findings

The results reported the presence of immunoglobulins IgG1, 2, 3 & 4, IgA1, IgM, and the complement factors C1q, C4b, and C9 in the serum samples obtained from SARS-CoV-2 positive HCWs. An increase in the immunocomplex was observed with increasing exposure to SARS-CoV-2 VOCs except for the Beta variant. A wide variation in immunocomplex was reported in individuals with 2 or more antigen exposure with one individual having a dominant IgG4 response.

The results indicated that IgG1 showed the strongest correlation with live virus neutralization data (NAbs). The second strongest correlation was shown by C1q. The IgG1 reactivity against the Alpha variant was found to be 37 to 51 percent higher than the Wuhan Hu-1 strain, for Delta similar reactivity was observed between this variant and the Wuhan Hu-1 strain, and for Beta, the reactivity was 52 to 55 percent of the original strain.

Changes in the IgM levels were observed only in the infection naïve group following vaccination while in some individuals changes in levels of IgG2 and IgG4 were observed. A higher IgA1 response was observed in individuals with only natural infection.

Furthermore, a higher IgM response accompanied by greater complement C4 and C9 binding was observed for Delta and Alpha VOCs. However, C1q binding was found to be independent of C4 and C9 since it showed a reduction in binding against Delta and Beta VOC. Also, it was observed that C1q had an overall stronger correlation with NAb as compared to IgG1.

The current study was, therefore, able to demonstrate the antibody responses in non-hospitalized healthcare workers approximately 3 weeks post-vaccination. Although LC-MS/MS multiplex assay is a research standard assay, it was designed so that it could be easily translated into clinical laboratory settings. Further research needs to be carried out to determine the effect of antibody response over time, the severity of infection from different variants, and the change in immunocomplex with age that would provide a better understanding of the evolving antibody-mediated immune response to SARS-CoV-2.

Limitations

The study had one significant limitation. It could not determine functional complement activation.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Suchandrima Bhowmik

Written by

Suchandrima Bhowmik

Suchandrima has a Bachelor of Science (B.Sc.) degree in Microbiology and a Master of Science (M.Sc.) degree in Microbiology from the University of Calcutta, India. The study of health and diseases was always very important to her. In addition to Microbiology, she also gained extensive knowledge in Biochemistry, Immunology, Medical Microbiology, Metabolism, and Biotechnology as part of her master's degree.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bhowmik, Suchandrima. (2022, February 18). Role of quantitative, multiplexed, targeted proteomics in determining variant-specific SARS-CoV-2 antibody response. News-Medical. Retrieved on July 03, 2022 from https://www.news-medical.net/news/20220218/Role-of-quantitative-multiplexed-targeted-proteomics-in-determining-variant-specific-SARS-CoV-2-antibody-response.aspx.

  • MLA

    Bhowmik, Suchandrima. "Role of quantitative, multiplexed, targeted proteomics in determining variant-specific SARS-CoV-2 antibody response". News-Medical. 03 July 2022. <https://www.news-medical.net/news/20220218/Role-of-quantitative-multiplexed-targeted-proteomics-in-determining-variant-specific-SARS-CoV-2-antibody-response.aspx>.

  • Chicago

    Bhowmik, Suchandrima. "Role of quantitative, multiplexed, targeted proteomics in determining variant-specific SARS-CoV-2 antibody response". News-Medical. https://www.news-medical.net/news/20220218/Role-of-quantitative-multiplexed-targeted-proteomics-in-determining-variant-specific-SARS-CoV-2-antibody-response.aspx. (accessed July 03, 2022).

  • Harvard

    Bhowmik, Suchandrima. 2022. Role of quantitative, multiplexed, targeted proteomics in determining variant-specific SARS-CoV-2 antibody response. News-Medical, viewed 03 July 2022, https://www.news-medical.net/news/20220218/Role-of-quantitative-multiplexed-targeted-proteomics-in-determining-variant-specific-SARS-CoV-2-antibody-response.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Scientists report autoimmunity from molecular mimicry between SARS-CoV-2 spike and human proteins